Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14402369 | 1.00 | CRBN (0.39) | CRBNSMN1; SMN2TDP1 | |
| SCHEMBL825867 | 0.85 | CRBN (0.40) | CRBNSMN1; SMN2TDP1 | |
| SCHEMBL10046427 | 0.85 | CRBN (0.40) | CRBNSMN1; SMN2TDP1 | |
| SCHEMBL825954 | 0.85 | CRBN (0.37) | CRBNSMN1; SMN2TDP1 | |
| SCHEMBL18155543 | 0.84 | ALDH1A1 (0.37) | CRBNSMN1; SMN2TDP1 | |
| SCHEMBL825882 | 0.82 | CRBN (0.38) | CRBNSMN1; SMN2TDP1 | |
| SCHEMBL14402291 | 0.80 | CRBN (0.44) | CRBNSMN1; SMN2TDP1 | |
| SCHEMBL825949 | 0.78 | CRBN (0.42) | CRBNSMN1; SMN2TDP1 | |
| SCHEMBL18155550 | 0.78 | CRBN (0.35) | CRBNSMN1; SMN2TDP1 | |
| SCHEMBL10046305 | 0.71 | CRBN (0.39) | CRBNSMN1; SMN2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2004614-B1 | TETRAHALOGENATED COMPOUNDS USEFUL AS INHIBITORS OF ANGIOGENESIS | US GOV HEALTH & HUMAN SERV (US) | 2016-10-19 | — | — | EP | disclosed |
| US-8143252-B2 | Tetrahalogenated compounds useful as inhibitors of angiogenesis | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2012-03-27 | — | — | US | disclosed |
| US-8143252-B2 | Tetrahalogenated compounds useful as inhibitors of angiogenesis | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2012-03-27 | — | — | US | disclosed |
| US-8143252-B2 | Tetrahalogenated compounds useful as inhibitors of angiogenesis | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2012-03-27 | — | — | US | disclosed |
| US-20090186913-A1 | Tetrahalogenated compounds useful as inhibitors of angiogenesis | THE GOVERNMENT OF THE UNITED STATES OF AMERICA DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2009-07-23 | — | — | US | disclosed |
| US-20090186913-A1 | Tetrahalogenated compounds useful as inhibitors of angiogenesis | THE GOVERNMENT OF THE UNITED STATES OF AMERICA DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2009-07-23 | — | — | US | disclosed |
| US-20090186913-A1 | Tetrahalogenated compounds useful as inhibitors of angiogenesis | THE GOVERNMENT OF THE UNITED STATES OF AMERICA DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2009-07-23 | — | — | US | disclosed |
| EP-2004614-A1 | TETRAHALOGENATED COMPOUNDS USEFUL AS INHIBITORS OF ANGIOGENESIS | The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services (US) | 2008-12-24 | — | — | EP | disclosed |
| WO-2007120669-A1 | TETRAHALOGENATED COMPOUNDS USEFUL AS INHIBITORS OF ANGIOGENESIS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2007-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186913-A1 | Tetrahalogenated compounds useful as inhibitors of angiogenesis | VHL, TEK, FLT4 | CRBN 1015/4885SMN1; SMN2 3789/4885TDP1 2273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.